Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

Article ID	Journal	Published Year	Pages	File Type
6062289	Journal of Allergy and Clinical Immunology	2016	16 Pages	PDF

Abstract

The combination of roflumilast with montelukast compared with montelukast alone improved lung function and asthma control in patients with moderate-to-severe asthma and deserves further study for this indication.

Keywords

Forced expiratory flow between 25% and 75% of forced vital capacity FeNO PDE-4 LTE4 ERS ANCOVA C-SSRS PEF FEF25-75%FVC IVRS ATS ACQ ICS SABA TEAE Asthma Long-acting β-agonist European Respiratory Society American Thoracic Society Short-acting β-agonist Chronic obstructive pulmonary disease COPD analysis of covariance Peak expiratory flow Fraction of exhaled nitric oxide Roflumilast LABA Interactive voice response system body mass index BMI forced vital capacity adverse event treatment-emergent adverse event phosphodiesterase 4 leukotriene E4 Columbia Suicide Severity Rating Scale Phosphodiesterase 4 inhibitors Montelukast Least Square map Asthma Control Questionnaire Inhaled corticosteroid

Related Topics

Life Sciences Immunology and Microbiology Immunology

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

Authors

Eric D. MD, Udo-Michael MD, Frank MD, Henrik MD,